Merck and Moderna Report Cancer Vaccine Reduces Melanoma Recurrence Risk
Audio narration · Coming soon
Merck and Moderna have released detailed results on an experimental vaccine designed to treat skin cancer. The vaccine reportedly cuts the risk of melanoma recurrence, marking a significant development in cancer treatment.
Why this matters
PRISM scored this story 65/100 for interest.
Originally published by nyt